Anidulafungin
(Synonyms: 阿尼芬净; LY303366) 目录号 : GC12754
A semisynthetic echinocandin antifungal
Cas No.:166663-25-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Antifungal assay [1]: | |
|
Fungi |
Aspergillus species |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
48 hrs |
|
Applications |
Anidulafungin potently inhibited Aspergillus species, with a MEC90 value of 0.02 mg/mL. The ranges of MIC and MEC of Anidulafungin against A. fumigatus, A. flavus, A. niger, A. glaucus group and A. versicolor were 0.00125 ~ 0.005 μ g/mL and 0.005 ~ 10.24 μ g/mL, respectively. |
| Animal experiment [2]: | |
|
Animal models |
Mice infected with strains FMR 9965, FMR 8756, FMR 9960, FMR 10084 or FMR 9966 of Aspergillus flavus |
|
Dosage form |
1, 5 or 10 mg/kg; i.p.; q.d., for 7 days |
|
Applications |
In Mice infected with strains FMR 9965, FMR 8756, FMR 9960, FMR 10084 or FMR 9966 of Aspergillus flavus, Anidulafungin at the doses of 5 and 10 mg/kg significantly prolonged survival. There were no substantial difference between the doses of 5 and 10 mg/kg. Moreover, in spleens and kidneys, Anidulafungin significantly reduced the fungal load in a dose-dependent manner. According to the bioassay results, at day 5 of treatment, the Anidulafungin serum levels were beyond the corresponding minimum effective concentrations of all strains. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Zhanel GG1, Karlowsky JA, Harding GA, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997 Apr;41(4):863-5. [2]. Calvo E, Pastor FJ, Mayayo E, Salas V, Guarro J. In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrob Agents Chemother. 2011 Mar;55(3):1290-2. |
|
Anidulafungin （LY-303366）is a synthetic derivative of echinocandin B, used as a drug of antifungal [1].
Anidulafungin has been reported to inhibit systemic isolates of Candida species with the MIC90 values of 0.08μg/ml, 0.32μg/ml, 0.32μg/ml and 5.12μg/ml for C.albicans (n=99), C.glabrata(n=18), C.tropicalis(n=10), and C.parapsilosis (n=10), respectively. In addition, Anidulafungin has been found to be active against Aspergillus species(n=20) with the MIC90 values of ~0.02μg/ml. Apart from these, Anidulafungin has been revealed to inactively restrain with the MIC90 values of >10.24μg/ml and 16μg/ml, for C.neoformans and B.dermatitidis, respectively [1].
References:
[1] Zhanel GG1, Karlowsky JA, Harding GA, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997 Apr;41(4):863-5.
[2]. Locke JB, et al. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6100-7.
| Cas No. | 166663-25-8 | SDF | |
| 别名 | 阿尼芬净; LY303366 | ||
| Canonical SMILES | O[C@H]1[C@H](C)CN(C([C@H]([C@H](C)O)NC([C@H]([C@@H]([C@@H](C(C=C2)=CC=C2O)O)O)NC([C@H](C3)N(C([C@H]([C@H](C)O)NC4=O)=O)C[C@@H]3O)=O)=O)=O)[C@@H]1C(N[C@H]([C@@H](C[C@@H]4NC(C5=CC=C(C6=CC=C(C(C=C7)=CC=C7OCCCCC)C=C6)C=C5)=O)O)O)=O | ||
| 分子式 | C58H73N7O17 | 分子量 | 1140.24 |
| 溶解度 | ≥ 30 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.877 mL | 4.385 mL | 8.7701 mL |
| 5 mM | 0.1754 mL | 0.877 mL | 1.754 mL |
| 10 mM | 0.0877 mL | 0.4385 mL | 0.877 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。